- Hutchinson–Gilford progeria syndrome (HGPS) is a rare and severe genetic disorder characterised by dramatic premature ageing beginning in early childhood. It is one of the most well‑studied progeroid syndromes and has provided profound insight into the molecular mechanisms that regulate nuclear architecture, genomic stability and the pace of human ageing. Children with HGPS appear normal at birth but soon develop features typically associated with advanced age, including growth failure, loss of subcutaneous fat, alopecia, joint stiffness and early cardiovascular disease. The condition progresses rapidly, with most affected individuals experiencing life‑threatening complications during adolescence.
- At the molecular level, HGPS is caused by a mutation in the LMNA gene, which encodes lamin A, a structural protein essential for maintaining nuclear shape and chromatin organisation. The mutation activates an abnormal splice site, producing a truncated and permanently farnesylated form of lamin A known as progerin. Progerin accumulates at the nuclear envelope, causing nuclear blebbing, altered chromatin structure, impaired DNA repair and increased genomic instability. These defects activate cellular senescence pathways and disrupt normal gene expression, leading to widespread tissue dysfunction and accelerated ageing phenotypes.
- One of the most striking aspects of HGPS is its impact on the cardiovascular system. Progerin accumulation damages vascular smooth‑muscle cells, leading to progressive arterial stiffening, loss of vascular elasticity and early onset of atherosclerosis. This vascular pathology is the primary cause of mortality in HGPS, typically resulting in myocardial infarction or stroke during the teenage years. The cardiovascular decline seen in HGPS closely resembles age‑related vascular disease in the general population, highlighting the shared mechanisms between premature and natural ageing.
- HGPS also affects skeletal development, skin integrity and metabolic function. Children often exhibit thin, tight skin, delayed tooth eruption, bone fragility and joint contractures. These symptoms reflect the inability of tissues to maintain structural integrity and repair damage due to chronic nuclear stress and persistent activation of DNA‑damage signalling. Although progerin is produced at very low levels in healthy individuals, its accumulation increases with age, suggesting that the molecular mechanisms underlying HGPS may also contribute to normal human ageing.
- Research into HGPS has led to significant advances in understanding nuclear‑lamina biology and has inspired therapeutic strategies aimed at reducing progerin toxicity. Farnesyltransferase inhibitors, which block the farnesylation of progerin, have shown partial clinical benefit by improving vascular stiffness and bone structure. Additional approaches, including antisense oligonucleotides, gene‑editing strategies and drugs targeting senescence pathways, are under investigation. These therapeutic developments not only offer hope for individuals with HGPS but also provide broader insight into interventions that may modulate ageing processes more generally.
- In summary, Hutchinson–Gilford progeria syndrome is a devastating premature‑ageing disorder caused by mutations in LMNA that produce the toxic protein progerin. Its clinical and molecular features reveal how nuclear‑lamina defects drive genomic instability, cellular senescence and systemic tissue decline. HGPS remains one of the most important models for studying human ageing, offering a unique window into the mechanisms that regulate longevity, tissue maintenance and age‑related disease.
